DNMT1 ‐Induced Downregulation of CBX7 Inhibits ERK Phosphorylation and Promotes Pancreatic Ductal Adenocarcinoma Progression
The FASEB Journal · 2025
DOI: 10.1096/fj.202402903r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2025. Verfasst von Haowei Shi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences…. Hauptthemen laut MEDLINE: DNA (Cytosine-5-)-Methyltransferase 1, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Polycomb Repressive Complex 1. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National High Level Hospital Clinical Research Funding.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancer types, characterized by an alarmingly low 5‐year survival rate. DNA methylation has been implicated in the progression of various tumors, with DNA methyltransferase 1 (DNMT1) being the most extensively studied enzyme in this context. However, the expression patterns and underlying mechanisms of DNMT1 in PDAC remain poorly understood. The levels of DNMT1 and CBX7 in PDAC tissues and cells were determined by IHC and Western blot. ChIP and dual‐luciferase reporter assays confirmed the interaction between DNMT1 and the CBX7 promoter. Cellular functions were evaluated through CCK‐8, wound healing, and transwell assays. The expression of MAPK‐related proteins was analyzed by Western blot. DNMT1 expression was upregulated in PDAC tissues and cell lines, whereas CBX7 expression was downregulated. Silencing DNMT1 inhibited cell proliferation, migration, and invasion in PDAC by modulating CBX7 expression. Moreover, DNMT1 methylates the CBX7 promoter region, leading to increased ERK phosphorylation, which subsequently drives tumorigenesis and metastasis in PDAC. DNMT1 promotes the malignant progression of PDAC through the CBX7/ERK pathway. Our study provides evidence for potential therapeutic targets for the comprehensive treatment of PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, P. R. China.
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
ORCID-Profile: Haowei Shi, Jinghai Song
Förderung
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Shi, H., Liu, X., Xing, C., Guo, S., Zheng, Y., Tan, W., Ge, Y., Xu, J., Li, Y., & Song, J. (2025). DNMT1 ‐Induced Downregulation of CBX7 Inhibits ERK Phosphorylation and Promotes Pancreatic Ductal Adenocarcinoma Progression. The FASEB Journal. https://doi.org/10.1096/fj.202402903r
Vancouver
Shi H, Liu X, Xing C, Guo S, Zheng Y, Tan W, et al. DNMT1 ‐Induced Downregulation of CBX7 Inhibits ERK Phosphorylation and Promotes Pancreatic Ductal Adenocarcinoma Progression. The FASEB Journal. 2025. doi:10.1096/fj.202402903r
BibTeX
@article{Shi2025,
author = {Shi, Haowei and Liu, Xu and Xing, Cheng and Guo, Shiqi and Zheng, Yangyang and Tan, Wendan and Ge, Yunpeng and Xu, Jingyong and Li, Yao and Song, Jinghai},
title = {DNMT1 ‐Induced Downregulation of CBX7 Inhibits ERK Phosphorylation and Promotes Pancreatic Ductal Adenocarcinoma Progression},
journal = {The FASEB Journal},
year = {2025},
doi = {10.1096/fj.202402903r}
}
EUVIMED